Literature DB >> 17655709

Should patients be informed about the risk of heparin-induced thrombocytopenia before prolonged low-molecular-weight heparin thromboprophylaxis post-trauma/orthopedic surgery?

Norbert Lubenow1, Peter Hinz, Axel Ekkernkamp, Andreas Greinacher.   

Abstract

OBJECTIVES: Heparin-induced thrombocytopenia (HIT) is an immune-mediated prothrombotic adverse drug effect that occurs less frequently with low-molecular-weight heparin (LMWH) than with unfractionated heparin (UFH) in post-trauma/orthopedic surgery patients. The life-threatening nature of HIT raises the question whether informed consent for this treatment-induced adverse effect should be obtained, particularly as LMWH is often continued during the outpatient period when clinical and platelet count monitoring become problematic. Paradoxically, refusal of thromboprophylaxis as a result of seeking informed consent could increase risk for thrombosis.
METHODS: We evaluated in patients undergoing routine LMWH thromboprophylaxis post-trauma/orthopedic surgery the feasibility of obtaining informed consent, using a standardized questionnaire to determine patient preferences. We also identified the proportion of HIT patients in our laboratory comprised of trauma/orthopedic surgery patients from 1995-1997 and 2002-2004 (time periods characterized, respectively, by UFH and LMWH thromboprophylaxis for this patient population).
RESULTS: None of 460 patients in whom informed consent was administered rejected LMWH thromboprophylaxis. The patients' perception of the informed consent process and the written information provided about the risk of HIT and its risk due to clinical consequences were highly favorable. From 1995-1997 to 2002-2004, the proportion of HIT identified among trauma/orthopedic surgery patients declined from 30.3% to 1.2% (P < 0.0001).
CONCLUSIONS: Obtaining informed consent about HIT is feasible in written form and does not cause refusal of LMWH thromboprophylaxis. Despite the uncommon occurrence of HIT during LMWH thromboprophylaxis, informed consent increases patient's awareness of this potentially life-threatening adverse drug effect, an outcome that could increase outpatient recognition of the diagnosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17655709     DOI: 10.1111/j.1600-0609.2007.00891.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  5 in total

1.  Venous thromboembolism: patient awareness and education in the pre-operative assessment clinic.

Authors:  Adam Haymes
Journal:  J Thromb Thrombolysis       Date:  2016-04       Impact factor: 2.300

2.  Complications related to deep venous thrombosis prophylaxis in trauma: a systematic review of the literature.

Authors:  Indraneel Datta; Chad G Ball; Lucas Rudmik; S Morad Hameed; John B Kortbeek
Journal:  J Trauma Manag Outcomes       Date:  2010-01-06

Review 3.  Inflammation and the host response to injury a large-scale collaborative project: patient-oriented research core standard operating procedure for clinical care X. Guidelines for venous thromboembolism prophylaxis in the trauma patient.

Authors:  Joseph Cuschieri; Brad Freeman; Grant O'Keefe; Brian G Harbrecht; Paul Bankey; Jeffrey L Johnson; Joseph P Minei; Jason Sperry; Michael West; Avery Nathens; Ernest E Moore; Ronald V Maier
Journal:  J Trauma       Date:  2008-10

4.  Awareness of venous thromboembolism and thromboprophylaxis among hospitalized patients: a cross-sectional study.

Authors:  Hind Almodaimegh; Lama Alfehaid; Nada Alsuhebany; Rami Bustami; Shmylan Alharbi; Abdulmalik Alkatheri; Abdulkareem Albekairy
Journal:  Thromb J       Date:  2017-07-19

5.  ExPeKT--Exploring prevention and knowledge of venous thromboembolism: a two-stage, mixed-method study protocol.

Authors:  Lorraine McFarland; Alison Ward; Sheila Greenfield; Ellen Murray; Carl Heneghan; Sian Harrison; David Fitzmaurice
Journal:  BMJ Open       Date:  2013-04-02       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.